ARTICLE | Clinical News
AIR001: Ph II INABLE-TRAINING started
December 30, 2016 9:09 PM UTC
Mast began the double-blind, placebo-controlled, U.S. Phase II INABLE-TRAINING trial to evaluate 80 mg inhaled AIR001 thrice daily for 12 weeks in about 68 patients undergoing exercise training as par...
BCIQ Company Profiles